Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
2(18%)
Results Posted
113%(9 trials)

Phase Distribution

Ph phase_4
6
55%
Ph phase_3
5
45%

Phase Distribution

0

Early Stage

0

Mid Stage

11

Late Stage

Phase Distribution11 total trials
Phase 3Large-scale testing
5(45.5%)
Phase 4Post-market surveillance
6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 35 (45.5%)
Phase 46 (54.5%)

Trials by Status

recruiting19%
withdrawn19%
completed873%
active_not_recruiting19%

Recent Activity

2 active trials
Showing 5 of 11
completedphase_4

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

NCT05535972
recruitingphase_3

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

NCT05757102
active_not_recruitingphase_3

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

NCT04651777
completedphase_3

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

NCT04937387
completedphase_4

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT04923347
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05535972Phase 4

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Completed
NCT05757102Phase 3

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
NCT04651777Phase 3

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Active Not Recruiting
NCT04937387Phase 3

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Completed
NCT04923347Phase 4

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03474081Phase 4

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03478696Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03478683Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03467425Phase 4

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Completed
NCT02729051Phase 3

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03376932Phase 3

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11